ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 312 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,286,613 | -11.5% | 47,884 | +17.4% | 0.00% | -33.3% |
| Q2 2023 | $1,453,901 | +39.2% | 40,784 | -0.8% | 0.00% | +50.0% |
| Q1 2023 | $1,044,385 | -39.7% | 41,117 | -3.8% | 0.00% | -50.0% |
| Q4 2022 | $1,733,362 | +406.8% | 42,722 | +313.2% | 0.00% | +300.0% |
| Q3 2022 | $342,000 | -7.1% | 10,340 | -0.9% | 0.00% | 0.0% |
| Q2 2022 | $368,000 | -76.1% | 10,432 | -3.3% | 0.00% | -66.7% |
| Q1 2022 | $1,538,000 | +10.0% | 10,791 | -48.8% | 0.00% | 0.0% |
| Q4 2021 | $1,398,000 | -8.9% | 21,069 | -14.3% | 0.00% | 0.0% |
| Q3 2021 | $1,534,000 | -44.0% | 24,574 | -25.7% | 0.00% | -50.0% |
| Q2 2021 | $2,739,000 | +138.0% | 33,068 | +90.6% | 0.01% | +100.0% |
| Q1 2021 | $1,151,000 | +20.1% | 17,351 | +39.1% | 0.00% | 0.0% |
| Q4 2020 | $958,000 | +3.8% | 12,475 | -41.8% | 0.00% | 0.0% |
| Q3 2020 | $923,000 | +7.3% | 21,443 | +7.7% | 0.00% | 0.0% |
| Q2 2020 | $860,000 | +123.4% | 19,915 | +48.7% | 0.00% | +50.0% |
| Q1 2020 | $385,000 | – | 13,393 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 908,474 | $24,410,696 | 22.12% |
| Western Financial Corp/CA | 820,239 | $22,039,822 | 16.16% |
| JOHNSON & JOHNSON | 247,598 | $6,652,958 | 2.45% |
| WEALTH EFFECTS LLC | 164,750 | $4,426,835 | 2.19% |
| M28 Capital Management LP | 67,400 | $1,811,038 | 2.08% |
| Privium Fund Management B.V. | 259,036 | $6,960,298 | 2.07% |
| Evolutionary Tree Capital Management, LLC | 51,266 | $1,377,517 | 1.78% |
| Avidity Partners Management LP | 1,063,897 | $28,586,912 | 1.15% |
| SECTORAL ASSET MANAGEMENT INC | 157,552 | $4,233,422 | 0.82% |
| Vivo Capital, LLC | 137,411 | $3,692,234 | 0.40% |